Antigenics shares spike as GSK launches PhIII

GlaxoSmithKline isn't the only company cheering the launch of a late-stage program for a shingles vaccine that could prove to be a blockbuster. Antigenics flagged its own role in the parade and was rewarded with a 20 percent spike in its share price. Antigenics supplied the adjuvant for GSK's vaccine. And as CEO Garo Armen notes in a release, the Lexington, MA-based company stands to gain a fresh revenue stream in the event the Phase III program ends on a bright note. Report

Suggested Articles

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.